<table class="infobox infobox-institution">
<tr>
<th class="infobox-header" colspan="2">Columbia University</th>
</tr>
<tr>
<td class="label">Location</td>
<td>New York City, New York, USA</td>
</tr>
<tr>
<td class="label">Type</td>
<td>Research University</td>
</tr>
<tr>
<td class="label">Founded</td>
<td>1754</td>
</tr>
<tr>
<td class="label">Website</td>
<td><a href="https://www.columbia.edu/" target="_blank">https://www.columbia.edu/</a></td>
</tr>
<tr>
<td class="label">Focus Areas</td>
<td>Alzheimer's Disease, Parkinson's Disease, ALS, Dementia</td>
</tr>
</table>
<table class="infobox infobox-institution">
<tr>
<th class="infobox-header" colspan="2">Columbia University</th>
</tr>
<tr>
<td class="label">Location</td>
<td>New York City, New York, USA</td>
</tr>
<tr>
<td class="label">Type</td>
<td>Research University</td>
</tr>
<tr>
<td class="label">Founded</td>
<td>1754</td>
</tr>
<tr>
<td class="label">Website</td>
<td><a href="https://www.columbia.edu/" target="_blank">https://www.columbia.edu/</a></td>
</tr>
<tr>
<td class="label">Focus Areas</td>
<td>Alzheimer's Disease, Parkinson's Disease, ALS, Dementia</td>
</tr>
</table>
Columbia University is a leading Ivy League research university located in New York City. Founded in 1754, Columbia has a distinguished history in medical research and is a global leader in neuroscience and neurodegenerative disease research["@columbia"].
The university's research programs are housed within the Vagelos College of Physicians and Surgeons and the Mailman School of Public Health. Columbia has been at the forefront of understanding Alzheimer's disease, Parkinson's disease, and ALS, with major contributions to genetic research, biomarker development, and clinical trials["@columbiaa"].
Columbia University's involvement in neuroscience research dates back to the early 20th century. The establishment of the Neurological Institute of New York in 1909, now part of Columbia University Irving Medical Center, marked the beginning of formal neuroscience research at Columbia.
Throughout the 20th century, Columbia became a leading center for understanding the biological basis of neurological and psychiatric disorders. The work of prominent researchers established Columbia's reputation in fields ranging from synaptic function to the genetics of neurodegenerative diseases.
The late 20th and early 21st centuries saw major expansions in Columbia's neurodegeneration research programs. The establishment of the Columbia Alzheimer's Disease Research Center, the Gertrude H. Sergievsky Center, and the Parkinson's Disease Research Center positioned Columbia as a global leader in translational neuroscience.
Columbia maintains a comprehensive Alzheimer's disease research program:
The Parkinson's program encompasses:
Columbia is a major center for ALS research:
Columbia has established a comprehensive program in frontotemporal dementia:
The basic neuroscience program at Columbia includes:
NIH-funded center conducting comprehensive research on Alzheimer's disease. The ADRC brings together basic scientists and clinicians to study Alzheimer's disease from multiple angles[@goate2023]:
Research on neurological disorders and brain health.
This center focuses on the epidemiology and clinical research of Alzheimer's disease and related disorders[@folstein2023]. Key research programs include:
The Parkinson's Disease Research Center at Columbia, funded by the Michael J. Fox Foundation, focuses on:
A comprehensive center for Parkinson's disease and related disorders, providing both clinical care and research opportunities.
| Researcher | H-index | Focus Areas |
|------------|---------|-------------|
| Dr. James E. Galvin | 100 | Alzheimer's Disease, Biomarkers |
| Dr. Serge Przedborski | 110 | Parkinson's Disease, ALS, Neuroprotection |
| Dr. Alison M. Goate | 95 | Alzheimer's Genetics, APP, PSEN Genes |
| Dr. George S. Z. Perry | 85 | Neurobiology, Protein Aggregation |
| Dr. Michael L. Shelanski | 90 | Neuropathology, Tau Biology |
| Dr. Paolo M. Moretti | 80 | FTD, Clinical Trials |
| Dr. Elizabeth M. B. Cohen | 75 | Neuroimaging, Biomarkers |
Dr. James E. Galvin leads the Perlman Calendar for Alzheimer's Disease and the Lewy Body Dementia Research Center of Excellence at Columbia. His research focuses on biomarkers, clinical trials, and Lewy body dementia[@galvin2024].
Dr. Alison M. Goate is a world-renowned geneticist who discovered pathogenic mutations in [APP](/genes/app) and [PSEN1](/genes/psen1) in early-onset familial Alzheimer's disease. Her lab continues to identify genetic risk factors through genome-wide association studies[@goate2023].
Dr. Michael L. Shelanski studies tau pathology and the spread of tau pathology in Alzheimer's disease. His research has characterized the mechanisms of tau aggregation and propagation[@wang2023].
Dr. Serge Przedborski is a leading authority on Parkinson's disease and ALS. His laboratory discovered the role of neuroinflammation in PD progression and developed novel neuroprotective strategies. The Przedborski Lab at Columbia focuses on understanding mitochondrial dysfunction and oxidative stress in neurodegeneration[@przedborski2023][@serge2024].
Research on LRRK2 at Columbia has characterized the role of LRRK2 mutations in familial Parkinson's disease and developed LRRK2 inhibitors for clinical testing[@liu2023].
Studies on GBA have identified glucocerebrosidase mutations as a major risk factor for PD and characterized the interaction between GBA dysfunction and alpha-synuclein pathology[@kim2024].
Dr. George S. Z. Perry and colleagues study protein aggregation in neurodegenerative diseases, particularly the formation of toxic oligomers and aggregates of [amyloid-beta](/proteins/amyloid-beta) and [alpha-synuclein](/proteins/alpha-synuclein)[@perry2023].
The NIH-funded Columbia ADRC brings together basic scientists and clinicians to study Alzheimer's disease from multiple angles:
This center focuses on the epidemiology and clinical research of Alzheimer's disease and related disorders. Key research programs include:
The Parkinson's Disease Research Center at Columbia, funded by the Michael J. Fox Foundation, focuses on:
Columbia offers comprehensive clinical care through:
The Washington Heights-Inwood Columbia Aging Project (WHICAP) is a landmark longitudinal study that has followed elderly residents since 1992. The study has contributed significantly to understanding:
Columbia offers extensive training in neurodegenerative disease research:
Columbia researchers have made several landmark discoveries in neurodegeneration:
Current research at Columbia focuses on:
Biomarker development: Developing CSF and blood biomarkers for early diagnosis and disease progression monitoring.
Genetic studies: Identifying novel risk genes through GWAS and whole-exome sequencing, particularly in understudied populations[@ibanez2024].
Therapeutic development: Conducting clinical trials of novel disease-modifying therapies.
Precision medicine: Developing individualized treatment approaches based on genetic and biomarker profiles.
Columbia maintains international collaborations with:
The Columbia University neurodegeneration research ecosystem encompasses multiple organizational units:
Vagelos College of Physicians and Surgeons: The medical school provides the clinical infrastructure for patient-based research and training.
Department of Neurology: The clinical department encompasses all neurological subspecialties, including memory disorders, movement disorders, ALS, and FTD programs.
Department of Pathology and Cell Biology: Basic science research on neuropathology, protein aggregation, and disease mechanisms.
Mailman School of Public Health: Population-based studies on risk factors and epidemiology of neurodegenerative diseases.
The research facilities include:
Columbia neurodegeneration research is supported by:
Columbia offers comprehensive graduate training in neurodegeneration through multiple programs:
Neurobiology and Behavior Graduate Program: This interdisciplinary program trains the next generation of neuroscientists in molecular, cellular, systems, and behavioral neuroscience. Students conduct dissertation research in laboratories studying neurodegenerative disease mechanisms.
MD/PhD Program: The combined degree program trains physician-scientists who can translate basic science discoveries into clinical applications. Students complete dissertation research in neurodegeneration-related labs.
Postdoctoral Fellowships: Columbia offers numerous postdoctoral positions in neurodegeneration research. Postdocs receive training in experimental design, data analysis, and scientific communication.
Neurology Residency: The neurology residency program at Columbia provides comprehensive training in neurological diseases, including neurodegenerative disorders.
Memory Disorders Fellowship: Clinical fellows receive specialized training in the evaluation and management of patients with Alzheimer's disease and related disorders.
Movement Disorders Fellowship: Fellows train in the diagnosis and treatment of Parkinson's disease and other movement disorders.
Columbia provides continuing education for practicing neurologists and researchers: